In homogeneous catalysis, the catalyst is in the same phase as the reactant. The number of collisions between reactants and catalyst is at a maximum.In a patent, 497-25-6, name is Oxazolidin-2-one, introducing its new discovery. Safety of Oxazolidin-2-one
Potassium alkoxides of N-acyl-oxazolidin-2-one-syn-aldols undergo stereoselective elimination reactions to afford a range of trisubstituted (E)-alphabeta-unsaturated amides in >95% de, that may be subsequently converted into their corresponding (E)-alphabeta-unsaturated acids or (E)-alphabeta-unsaturated oxazolines in good yield. syn-Aldols derived from alphabeta-unsaturated aldehydes gave their corresponding trisubstituted (E)-alphabeta-unsaturated-amides with poorer levels of diastereocontrol, whilst there was a similar loss in (E)-selectivity during elimination of syn-aldols derived from chiral aldehydes. These elimination reactions proceed via rearrangement of the potassium alkoxide of the syn-aldol to a 1,3-oxazinane-2,4-dione enolate intermediate that subsequently eliminates carbon dioxide to afford a trisubstituted (E)-alphabeta-unsaturated amide. The (E)-selectivity observed during the ElcB-type elimination step has been rationalised using a simple conformational model that employs a chair-like transition state to explain the observed stereocontrol. The Royal Society of Chemistry 2005.
We’ll also look at important developments in the pharmaceutical industry because understanding organic chemistry is important in understanding health, medicine, the role of 497-25-6, and how the biochemistry of the body works.Safety of Oxazolidin-2-one
Reference：
Oxazolidine – Wikipedia,
Oxazolidine | C3H521NO – PubChem